Financial News
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
May 03, 2023 at 14:20 PM EDT
Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
More News
View More
Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain ↗
Today 17:23 EST
Qualcomm’s Bulls Are Running Out of Room to Be Wrong ↗
Today 16:21 EST
Amazon Just Did This—and It Didn't End Well Last Time ↗
Today 15:43 EST
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
